Hiab and FSP enter into agreement on the transfer of surface treatment functions in Poland
23.4.2021 12:01:00 EEST | Business Wire | Press release
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland as of April 2021. Following the partnership FSP will provide Hiab Poland the surface treatment services and the expertise in development techniques.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005017/en/
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland. (Photo: Business Wire)
The surface treatment operation in Hiab’s Stargard multi-assembly unit and its associated professionals will transfer to FSP under their current employment conditions. The purpose of the agreement is to intensify the cooperation between Hiab and FSP so that the parties can focus on their own core competencies and improve business development.
For several years, FSP has been responsible for the surface treatment of Hiab’s MULTILIFT products in Finland. We have had an intense collaboration and established joint investments with Hiab. FSP is seeking international growth. ‘Thus, intensifying the collaboration further with Hiab was an anticipated consequence’, said FSP’s Chief Executive Officer Jarno Huttunen.
The new partnership will ensure Hiab continues with the latest in desired processes and technology. The facilities are equipped with a modern, cutting edge anti-corrosion treatment production line with an option for e-coating. The number of our personnel in Poland now consists of over a hundred professionals. These factors will provide us with more prospects in the future and enhance our resilience. This of course upgrades FSP’s service level in Poland, Huttunen continued. The multi-assembly unit is in the city of Stargard, in Poland.
The extension of the cooperation between the two giants creates a competitive advantage in surface treatment quality and technological leadership.
Hiab is a part of Cargotec Corporation. Cargotec enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions.
FSP has been Hiab’s business associate for several years. FSP's role as Hiab's surface treatment expert partner is to create added value. We believe that FSP continues to respond to our demands in both delivery accuracy and quality, said Hiab’s Barry McGrane - Senior Vice President of LM Loader Cranes
Together we will continue to increase our competitive advantage in the fields of quality and technological leadership. The objective is to improve the efficiency, innovation, reliability of the surface treatment operations in the short and long term and we look forward to strengthening the partnership between both businesses,” Barry McGrane continues.
Cargotec Hiab
Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions. Hiab's class-leading load handling equipment includes HIAB, EFFER and ARGOS loader cranes, LOGLIFT and JONSERED forestry and recycling cranes, MOFFETT and PRINCETON truck mounted forklifts, MULTILIFT skip loaders and hooklifts, and tail lifts under the ZEPRO, DEL, and WALTCO brands. As the industry pioneer and with a proud 75 year history, Hiab is committed to be the preferred partner and solution provider to its customers and shape the future of intelligent load handling. www.hiab.com Hiab is part of Cargotec Corporation. www.cargotec.com
FSP Finnish Steel Painting Oy
FSP Finnish Steel Painting Oy is one of Europe's leading surface treatment companies. We employ more than 300 professionals and have a turnover of approximately EUR 26 million.
We offer industrial surface treatment and related design and value-added services. Our service covers the surface treatment process throughout the product's life cycle, from the definition of operating conditions to surface treatment, inspections and post-warranty maintenance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005017/en/
Contact information
Mr. Jarno Huttunen
CEO
FSP Finnish Steel Painting Oy
Tel +358 50 400 2082
jarno.huttunen@fspcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom